Reach Us +44-7482-864460
Treatment of Nonsense Mutations Using Stop Codon Read-through Therapeutics and Creation of Animal Models Using CRISPR-Cas9 | OMICS International
ISSN: 1747-0862
Journal of Molecular and Genetic Medicine
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Treatment of Nonsense Mutations Using Stop Codon Read-through Therapeutics and Creation of Animal Models Using CRISPR-Cas9

Kelly A. Turner1,2,3 and Francis YM Choy1*

1Centre for Biomedical Research, Department of Biology, University of Victoria, 3020, Station CSC, Victoria, BC, V8W 3N5, Canada

2Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 1L3

3Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada V6T 1Z3

Corresponding Author:
Francis Y.M. Choy
Centre for Biomedical Research
Department of Biology, University of Victoria
3020, Station CSC, Victoria, BC
V8W 3N5, Canada
Tel: 1-250-721-7107
Fax: 1-250-721-7120
E-mail: [email protected]

Received Date: May 23, 2015 Accepted Date: June 27, 2015 Published Date: July 04, 2015

Citation:Turner KA, Choy FYM (2015) Treatment of Nonsense Mutations Using Stop Codon Read-through Therapeutics and Creation of Animal Models Using CRISPR-Cas9. J Mol Genet Med 9:172. doi:10.4172/1747-0862.1000172

Copyright: ©2015 Turner KA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Molecular and Genetic Medicine


Premature termination codons result when a mutation within a protein coding sequence causes an amino acidencoding sense codon to be interpreted as a stop codon. Often, this results in truncation and destruction of the mRNA transcript or a non-functional protein. Nonsense mutations account for approximately 11% of all described mutations that contribute to disease. A number of therapeutics, including suppressor tRNAs, gentamicin, and PTC124, have been developed that purport to promote the “read-through” of these premature termination codons so that they are interpreted as sense codons. This, theoretically, would reconstitute the full-length transcript and restore protein/enzyme function and ameliorate disease symptoms. Currently, the implementation of such therapeutics in a clinical setting has been slow due to factors such as toxicity and inefficiency. We will discuss these hurdles as well as the difficulties associated with determination of the required protein/enzyme level to reduce symptoms as well as breakthroughs in genome editing to create nonsense mutation animal models using the clustered regularly interspersed short palindromic repeats-CRISPR-associated protein 9 system.

he required threshold of reconstituted protein activity to ameliorate symptoms.


Specific Treatments

Suppressor tRNAs

Historically, the use of suppressor tRNAs was the first method that demonstrated read through ability in β-thalassemia patients with nonsense mutations [5]. β-thalassemia is an autosomal recessive disorder that results from mutations in the β-globin locus on chromosome 11q15.5, which lead to profoundly deficient hemoglobin synthesis and anemia [6]. Temple et al. designed a tRNA anticodon for lysine with two mismatches in the recognition sequence so that a specific stop codon (UAG) became recognized as a lysine codon. This was referred to as a suppressor tRNA. Subsequently, if this stop codon was encountered, the suppressor tRNA would incorporate a lysine at that site instead of terminating translation. Xenopus oocyte nuclei were injected with a plasmid containing the modified tRNALys gene and later injected with reticulocyte mRNA from a β-thalassemia patient with a lysine to UAG nonsense mutation. Importantly, the mutated tRNALys would not recognize the natural stop codon in β- globin as it has a UAA sequence. The oocytes were incubated for 48 hours and the β-globin protein was isolated using a monoclonal antibody. When the protein was run on a gel, it had the same electrophoretic mobility as normal β-globin, suggesting that the incorporation of lysine at the premature stop codon reconstituted the full-length protein.

In vivo studies in mice modeling Duchenne muscular dystrophy (DMD) were later carried out and the mice showed a 2.5% increase in dystrophin expression in muscle fibers when injected with suppressor tRNAs [7]. These findings suggested that human genetic diseases caused by nonsense mutations may also be amenable to treatment using such an approach. However, the usual roadblocks associated with gene therapy have impeded a clinical application of suppressor tRNAs. Various gene delivery systems such as retroviral and adenoviral transfection as well as liposomal packaging have been described, but each are associated with the drawbacks of insertional mutagenesis [8], immune rejection [9], and toxicity [10], respectively. Additionally, assuming that the suppressor tRNA gene is actually expressed, the mature tRNA must then be recognized and charged by specific aminoacyl synthetases [11]. The modification of the tRNA may result in decreased recognition and inefficient charging by the aforementioned enzymes, which would lead to a decrease in readthrough. An additional hurdle for the exogenous suppressor tRNA is competition with release factors that recognize the PTC and catalyze the cleavage of the polypeptide from the ribosome [12]. Importantly, suppressor tRNAs are unable to distinguish between natural stop codons and premature stop codons, which could have disastrous consequences for normal protein translation. Currently, the implementation of suppressor tRNAs as a therapy for PTC readthrough does not appear to be a viable option until gene delivery is improved and safety concerns associated with natural stop codon readthrough are addressed.


A pharmaceutical compound that shows nonsense suppression activity is the aminoglycoside gentamicin. Aminoglycosides are a class of antibiotics that selectively bind to the bacterial ribosomal decoding center, which leads to misincorporation of amino acids in the growing peptide chain and improper protein synthesis [13]. A subset of aminoglycosides, including gentamicin, occasionally bind to eukaryotic ribosomes as well [14], which leads to misincorporation of amino acids at PTCs, but not at natural stop codons. The selectivity of gentamicin for promoting read through at PTCs but not at natural stop codons is not well-understood, although it was proposed that the increased distance between the PTC and polyA-binding protein of the mRNA closed loop complex creates a lag time whereupon a charged tRNA can accidentally enter the ribosomal A-site and continue synthesis of the polypeptide chain [15] (Figure 1a and b).


Figure 1: Translation termination at normal versus premature stop codons. a) Normal translation termination. Release factors (green triangle) bind to the A site of the ribosome and through interactions with poly(A) binding proteins (orange trapezoid), facilitate cleavage of the polypeptide chain. b) Translation termination at PTCs. The release factors and poly(A) binding proteins are farther apart (red arrow), creating a lag time in which the PTC may be susceptible to read-through. This property can be enhanced by nonsense suppression drugs.

The first in vivo application of stop codon read-through using gentamicin was in mdx mice modeling DMD [16]. DMD is an Xlinked muscular degenerative disorder that results from a profound deficiency or absence of the dystrophin protein in muscle fibers [17]. Data obtained from The Human Gene Mutation Database suggests that nonsense mutations account for 20% of all mutational events leading to DMD [3]. Subsequently, nonsense suppression therapies could benefit a large subset of DMD patients. In the pioneering in vivo experiment, mdx mice were treated with gentamicin for 14 days and subsequently analyzed for creatine kinase (CK) activity (upregulated during muscle death) and full-length dystrophin incorporation into muscles. The mdx mice treated with gentamicin had decreased creatine kinase activity compared to untreated mdx mice, with levels approaching those of normal control mice. As well, western blot analysis of dystrophin in muscles using an antibody directed against the C-terminal-region of the dystrophin protein showed a significant increase in the amount of full-length dystrophin present in muscles compared to the untreated mice. Overall, treatment with gentamicin was able to restore 10-20% of normal dystrophin levels in muscle of mdx mice, which provided some protection against muscle injury but did not restore full function of the muscles. The authors postulated that daily administration of gentamicin in humans (below the maximum recommended dose) could provide some increase in dystrophin levels in patients with DMD.

Building on the results from the murine model, Wagner et al. treated human DMD patients with sub-toxic levels of gentamicin for two weeks. At the end of the trial period, no full-length dystrophin was detected in any of the patients; however, serum CK levels had decreased, which seemed contradictory as CK activity is used as a biomarker for damaged muscle cells and a proxy for diagnosing DMD. A decrease in CK would indicate that dystrophin levels had increased [18]. Wagner et al. postulated that the discrepancy was due to less daily activity in patients during the experiment and that CK levels are not an accurate marker of disease. They recommended that higher dosages of gentamicin should be used in future studies for longer periods of time; however, they cautioned that dose escalation could lead to nephrotoxicity and ototoxicity. Their alternative recommendation is to explore other aminoglycosides that are less toxic or use a rational design approach to develop similar molecules that demonstrate readthrough ability, but are non-toxic.

A recent in vitro study examined the use of gentamicin on PTC skin fibroblasts from a subset of patients with xeroderma pigmentosum, a severe skin condition caused by mutations in XPC , which encodes an enzyme associated with DNA repair following ultraviolet radiation exposure. Following gentamicin treatment, the amount of XPC mRNA as well as XPC protein significantly increased. The authors believe that even a small increase in read-through (3-5% of normal XPC mRNA and 29% of normal XPC protein) may decrease the risk of skin cancer for these patients, and topical delivery of the drug may circumvent the concerns associated with aminoglycoside toxicity and provide a method of personalized medicine to alleviate the cutaneous symptoms [19].


Another pharmacological compound that may demonstrate PTC read-through ability is PTC124 (Ataluren; 3-[5-(2-fluorophenyl)-1,2,4- oxadiazol-3-yl]benzoic acid). PTC124 was discovered from a highthroughput screen of approximately 800,000 compounds using a firefly luciferase (FLuc) activity assay system [20]. A construct was created in which the luciferase gene contained an in-frame PTC. Human embryonic kidney cells were then transfected with the construct. Theoretically, if a compound could successfully suppress the PTC, then the full-length luciferase transcript would be translated and increased fluorescence could be detected. The candidate compound also had to fulfill other requirements such as high oral bioavailability, low toxicity, and minimal off-target interactions in order to be considered for further investigation. PTC124 showed all of these characteristics and had the ability to suppress PTCs in human DMD primary cell cultures and mdx mice, thereby increasing dystrophin levels in vitro and in vivo and ameliorating disease symptoms in the mice, such as contractioninduced muscle injury, which is the major functional deficit in mdx mice as well as DMD patients [20].

The success of PTC124 in mdx mice prompted clinical trials for the drug in human DMD patients. Unfortunately, in the phase IIb clinical trial, no significant changes were observed between the experimental and placebo groups over the 48-week period and the trial was discontinued [21]. As other laboratories attempted to replicate the results obtained by Welch et al. on other cell lines, conflicting results began to emerge. In order to determine whether the up-regulation of the luciferase signal was due to PTC suppression or an artifact of the assay, various hypotheses were proposed that could explain the results obtained by Welch et al. [22,23]. Experiments performed by Auld et al. demonstrated that PTC124 did not promote PTC read-through, but simply stabilized the few full-length luciferase transcripts that arose from natural, “leaky” nonsense suppression, thus resulting in a significant increase in fluorescence over the background. Also, when a structurally dissimilar reporter enzyme was used (Renilla reniformis luciferase, or RLuc), no fluorescence was detected [22]. The authors suggested that appropriate control experiments should have been carried out, which could have determined that FLuc is a molecular target of PTC124 and not a suitable reporter for this class of compound.

Despite the controversial results of the FLuc assay, PTC124 has been used in a number of in vitro studies of very different diseases resulting from nonsense mutations, including cystic fibrosis (CF) [24], Mucopolysaccharidoses types I and VI [25,26], pulmonary aterial hypertension [27], and methylmalonic aciduria [28], all with positive results. Since these deficient proteins are functionally diverse, it is unlikely that the mechanism of restoration seen in the FLuc assay (binding and subsequent stabilization of the enzyme) was the same mechanism employed to restore the different proteins associated with the aforementioned diseases.

Furthermore, PTC124 has been used in clinical trials with CF patients, and phase III data suggested that PTC124 improved several symptom parameters relative to controls, however, the restored protein function was not significant enough to have a therapeutic benefit [29]. The small increase in protein function suggests that PTC124 may be effective in treating diseases in which the required protein threshold is low, but few studies to date have explored such disorders.

General Hurdles

The application of the aforementioned therapies as well as other proposed treatments for PTC read-through in the clinic has been slow due to not only intrinsic shortcomings of the therapies themselves, but also the difficulty of modeling the diseases in animals. Another significant hurdle is the large variability in the level of protein/enzyme activity that is required to alleviate disease symptoms; these are often disease-specific, patient-specific, and depend upon the context of the mutation. Upon closer scrutiny, the seemingly ‘cure-all’ nature of these drugs against diseases caused by premature stop codons is a hasty assumption as the technology is still in its infancy, and a number of obstacles still remain.

Animal models

A significant factor that has stalled the implementation of PTC suppression therapy is the lack of animal models carrying the precise nonsense mutation associated with the various diseases. Currently, knockout animal models are costly and take a minimum of several months to produce, and conventional methods knock out large portions of the gene of interest [30]. It is more difficult to introduce a single nucleotide substitution at a precise location in the genome that creates an in-frame premature stop codon. However, a newly emerging technique known as CRISPR-Cas (clustered regularly interspaced short palindromic repeats-CRISPR-associated protein) co-opts an endogenous prokaryotic defense mechanism that uses RNA to guide the degradation of foreign DNA [31]. This CRISPR-Cas system can be used to create double stranded DNA breaks at very precise locations in the genome and allow for subsequent non-homologous end joining (NHEJ) gene disruption to create small indels, or precise editing via homology directed repair (HDR), if a modified DNA oligo complementary to the cleaved locus is present [32] (Figure 2). For example, it is possible to introduce a base substitution at a precise locus in the genomic sequence that converts a sense codon into an in-frame PTC.


Figure 2: Representation of the mechanism of genome editing using CRISPR-Cas9. a) Cells are transfected with Cas9 protein (green) bound to crRNA to serve as a guide to the genomic location. Cells are also transfected with a DNA oligo complementary to the region of interest and containing the desired mutation, in this case, a nonsense mutation. b) The Cas9 protein binds to the region of interest and creates a doublestranded break. The DNA oligo serves as a template for homologous DNA repair. c) The nonsense mutation has been incorporated into the gene of interest.

The aforementioned method was applied to create precise mutations in mouse embryos with high efficiency and in significantly less time (a few weeks instead of many months) compared to conventional methods [33]. Zygotes were co-injected with guide CRISPR RNAs (crRNAs) complementary to a specific region in the Tet1 gene, Cas9 mRNA, and single stranded DNA oligos that would serve as a template for HDR once the target locus was cleaved. The DNA oligo was designed with two base changes so that a SacI restriction site was converted to an EcoRI site. Blastocysts were derived from these zygotes and the DNA was isolated and subsequently amplified and digested with EcoRI to detect whether the oligo facilitated HDR. Six out of nine embryos incorporated an EcoRI site at the Tet1 locus. These blastocysts were injected into a surrogate female and 21% developed to term and resulted in viable offspring [33]. As an interesting aside, Wang et al. were also able to induce the simultaneous disruption of five genes in mouse embryonic stem cells in a single step using this same method, but with 5 different crRNAs and five different DNA oligos specific to the genes of interest. After restriction fragment length polymorphism analysis, it was determined that 10% of the clones carried mutations in all five genes. The results obtained by Wang et al. demonstrate that it is no longer difficult to model diseases that result from very specific mutations.

Building upon the results of Wang et al, Long and colleagues hypothesized that they could correct the PTC in the Dmd gene in mdx mouse zygotes in order to prevent muscular dystrophy [34]. crRNAs approximately 20 bp in length were designed as the guide strand to target the PTC locus in exon 23 and later injected into the zygotes along with Cas9 mRNA and a template with the correct Dmd sequence to facilitate HDR. The zygotes were implanted into a surrogate female and the resulting mice were genetic mosaics with 2-100% correction in the Dmd gene, either via HDR or NHEJ, the latter of which created a small deletion of bases surrounding the PTC, but still lead to fulllength dystrophin expression [34]. Myofibers from mice with varying levels of restored dystrophin function (17%, 41%, and 83%) were studied and none showed the characteristic mdx phenotype. As well, serum CK levels were comparable to controls and muscle performance tests showed that the CRISPR mice had enhanced muscle performance compared to the mdx mice. Long et al. concluded that their results could be adapted for human somatic cell therapy if gene delivery systems are improved and if the efficiency of HDR could be increased, because terminally differentiated cells, including myocytes in myofibers and cardiomyocytes, lack homologous recombination proteins [35].

The application of CRISPR technology to correct deleterious mutations is also potentially useful in regenerative medicine. In essence, somatic cells such as cultured skin fibroblasts, or blood cells that can be obtained noninvasively from patients, are reprogrammed using transcriptional factors c-Myc, Klf4, Oct4, and Sox2 (MKOS) to become induced pluripotent stem cells (iPSCs) [36]. Upon correction of the disease-causing mutation(s) using CRISPR technology, iPSCs with the wild type sequence will then be differentiated to the desired cell types, e.g. hematopoietic stem cells for treatment of thalassemia and dopaminergic neurons for treatment of Parkinson’s disease, and infused/transplanted back to the patient. Recently, we have generated iPSCs from cultured skin fibroblasts from patients with type 2 Gaucher disease [37] and Sanfilippo syndrome B [38] by using a Sendai virus vector carrying the MKOS factors for a CRISPR-mediated DNA repair study. The Sendai virus is a non-integrating virus and thus circumvents the pitfalls of insertional mutagenesis and oncogenesis associated with retroviral and lentiviral reprogramming vectors [39].

Determining protein threshold

Another impediment to the ‘cure-all’ promise of these drugs/ treatments is the extreme heterogeneity in the level of protein/enzyme activity required to ameliorate disease symptoms. For recessive diseases, heterozygote carriers have 50% of normal protein function and are usually asymptomatic [40]; but it is largely variable as to where the real disease threshold is. For example, patients with Mucopolysaccharidosis type I – Hurler’s (MPS-I-H) syndrome only require 0.4-1% of normal α-L-iduronidase enzyme activity to alleviate symptoms [41], whereas patients with protein C deficiency require at least 50% protein function or else they will express the thrombotic disease [42]. Unfortunately, many diseases have not been characterized this way; it is simply mentioned that due to recessive inheritance, heterozygote carriers (assumed to have 50% of normal protein/enzyme activity) are unaffected. In future, it will be paramount that the protein threshold of every disease attributed to a premature stop codon be determined in order to devise personal treatment options for a genotypic subset of patients. For example, if a patient has MPS-I-H, PTC suppression therapy alone may be adequate to correct the disease phenotype, by virtue of the low threshold (0.4-1% of normal iduronidase). However, if a patient has DMD, it would be advisable that the patient combines stop codon read-through therapies with other symptom management strategies.


Current PTC suppression therapies have achieved modest increases in protein function; however, these increases are not sufficient to have a therapeutic benefit at present. For example, Malik et al. treated sixteen boys with DMD with gentamicin for six months and one patient showed the greatest increase in dystrophin expression in muscle from 4.5% to 15.44% [43], Unfortunately, at least 20-30% of normal dystrophin is required to attenuate DMD symptoms [44]. In order for these treatments to be adapted to a clinical setting, efficiency of read-through must increase, toxicity of the proposed compounds must decrease, delivery mechanisms for gene therapy must improve, and the creation of animal models for the study of these very specific mutational events must be more cost effective and efficient.


This work is supported by an operating grant from the Sanfilippo Children’s Research Foundation to F.Y.M.C and a research fellowship from the Natural Sciences and Engineering Research Council of Canada to K.A.T.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 14907
  • [From(publication date):
    August-2015 - Oct 23, 2019]
  • Breakdown by view type
  • HTML page views : 10810
  • PDF downloads : 4097